O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII

AAPS Journal

Volumn 9, Issue 2, 2007, Pages

  Miclea, Razvan D ^a   Purohit, Vivek S ^b   Balu Iyer, Sathy V ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

B domain deleted recombinant factor VIII; Excipient; Immunogenicity; Inhibitor development; O phospho L serine; Physical stability; Protein formulation

Indexed keywords

BLOOD CLOTTING FACTOR 8; EXCIPIENT; LIPID; NEUTRALIZING ANTIBODY; PHOSPHOSERINE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANISOTROPY; ANTIBODY TITER; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FATALITY; FLUORESCENCE ANALYSIS; GEL PERMEATION CHROMATOGRAPHY; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN LOCALIZATION; SUBSTITUTION THERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; COAGULANTS; DISEASE MODELS, ANIMAL; DRUG STABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; EXCIPIENTS; FACTOR VIII; HEMOPHILIA A; HUMANS; LIPOSOMES; MICE; MICE, KNOCKOUT; NEUTRALIZATION TESTS; PARTIAL THROMBOPLASTIN TIME; PHOSPHOSERINE; PROTEIN BINDING; PROTEIN FOLDING;

EID: 34447296486     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj0902028     Document Type: Article

References (39)

1. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem. 1988;263:6352-6362.
2. Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost. 2005;3:1257-1265.
3. Kaufman RJ. Biological regulation of factor VIII activity. Annu Rev Med. 1992;43:325-339.
4. Lamer AJ. The molecular pathology of haemophilia. Q J Med. 1987;63:473-491.
5. Klinge J, Ananyeva NM, Hauser CA, Saenko EL. Hemophilia A - from basic science to clinical practice. Semin Thromb Hemost. 2002; 28:309-322.
6. Lollar P. Molecular characterization of the immune response to factor VIII. Vox Sang. 2002;83:403-408.
7. Fijnvandraat Y, Bril WS, Voorberg J. Immunobiology of inhibitor development in hemophilia A. Semin Thromb Hemost. 2003;29:61-68.
8. Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost. 2003;1:1777-1784.
9. Pratt KP, Shen BW, Takeshima. K, Davie EW, Fujikawa Y, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature. 1999;402:439-442.
10. Pratt KP, Qian J, Ellaban E, et al. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost. 2004;92:522-528.
11. Purobit VS, Jr, Ramani K, Jr, Sarkar R, Jr, Kazazian HH, Jr, Balasubramanian SV. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex. J Biol Chem. 2005;280:17593-17600.
12. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA. 1986;83:5939-5942.
13. Pittman DD, Alderman EM, Tomkinson KN, Wang JR, Giles AR, Kaufman RL Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood. 1993;81:2925-2935.
14. Ramani K, Balasubramanian SV. Fluorescence properties of Laurdan in oochleate phases. Biochim Biophys Acta. 2003;1618:67-78.
15. Over J. Methodology of the one-stage assay of Factor VIII (VIII:C). Scand J Haematol Suppl. 1984;41:13-24.
16. Ramani K, Purohit V, Middaugh CR, Balasubramanian SV. Aggregation kinetics of recombinant human FVIII (rFVIII). J Pharm Sci. 2005;94:2023-2029.
17. Lakowicz J. Principles of Fluorescence Spectroscopy. New York, NY: Kluwer Academic/Plenum; 1999.
18. Wu H, Reding M, Qian J, et al. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost. 2001;85:125-133.
19. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73:247-251.
20. Saenko EL, Scandella D, Yakhyaev AV, Greco NJ. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets. J Biol Chem. 1998;273:27918-27926.
21. Gilbert GE, Drinkwater D. Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine. Biochemistry. 1993;32:9577-9585.
22. Purohit VS, Ramani K, Kashi RS, Durrani MJ, Kreiger TJ, Balasubramanian SV. Topology of factor VIII bound to phosphatidylserine-containing model membranes. Biochim Biophys Acta. 2003;1617:31-38.
23. Griffin BD, Micklem LR, McCann MC, James K, Pepper DS. The production and characterisation of a panel of ten murine monoclonal antibodies to human procoagulant factor VII. Thromb Haemost. 1986;55:40-46.
24. a. Biochemistry. 2002;41:5675-5684.
25. Li X, Gabriel DA. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding. Biochemistry. 1997;36:10760-10767.
26. Ramani K, Purohit VS, Miclea RD, Middaugh CR, Balasubramanian SV. Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII). J Pharm Sci. 2005;94:1288-1299.
27. Falls LA, Furie B, Furie BC. Role of phosphatidylethanolamine in assembly and function of the factor IXa-factor VIIIa complex on membrane surfaces. Biochemistry. 2000;39:13216-13222.
28. Grillo AO, Edwards KL, Kashi RS, et al. Conformational origin of the aggregation of recombinant human factor VIII. Biochemistry. 2001;40:586-595.
29. Derrick TS, Kashi RS, Durrani M, Jhingan A, Middaugh CR. Effect of metal cations on the conformation and inactivation of recombinant human factor VIII. J Pharm Sci. 2004;93:2549-2557.
30. Fatouros A, Liden Y, Sjostrom B. Recombinant factor VIII SQ - stability of VIII:C in homogenates from porcine, monkey and human subcutaneous tissue. J Pharm Pharmacol. 2000;52:797-805.
31. Wang W, Kelner DN. Correlation of rFVIII inactivation with aggregation in solution. Pharm Res. 2003;20:693-700.
32. Carpenter JF, Kendrick BS, Chang BS, Manning MC, Randolph TW. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol. 1999;309:236-255.
33. Kendrick BS, Carpenter JF, Cleland JL, Randolph TW. A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma. Proc Natl Acad Sci USA. 1998;95:14142-14146.
34. Kendrick BS, Chang BS, Arakawa T, et al. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: role in restricted conformational mobility and compaction of native state. Proc Natl Acad Sci USA. 1997;94:11917-11922.
35. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood. 2002;99:1215-1223.
36. Qian J, Jr, Borovok M, Jr, Bi L, Jr, Kazazian HH, Jr, Hoyer LW. Inhibitor antibody development and T-cell response to human factor VIII in murine hemophilia A. Thromb Haemost. 1999;81:240-244.
37. Hoffmann PR, Kench JA, Vondracek A, et al. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J Immunol. 2005; 174:1393-1404.
38. Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab. 1980;51:691-697.
39. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8:E501-E507.